01—Abstract
Summary
Summary of the 10-Q filed August 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Revolution Medicines, Inc. (RVMD) reported its Form 10-Q for the quarter ended June 30, 2025, describing itself as a clinical-stage precision oncology company developing RAS(ON) inhibitors for RAS-addicted cancers.
Research and development expense rose to $224.1 milliona for the three months ended June 30, 2025, from $134.9 million a year earlier, and net loss widened to $247.8 million from $133.2 million. For the six months, net loss was $461.2 million versus $249.2 million. The company reported $2.1 billion in cash, cash equivalents and marketable securities and an accumulated deficit of $2.2 billion, and states that existing resources will fund planned operations for at least 12 months.
The most significant financing event was a June 2025 revenue participation right purchase and sale agreement with Royalty Pharma, under which Royalty Pharma paid an upfront $250.0 millionb in exchange for tiered royalties on worldwide net sales of daraxonrasib (RMC-6236) and, if approved for an overlapping indication, zoldonrasib (RMC-9805). The filing also describes up to $1.0 billion of additional potential royalty purchases tied to milestones, and a senior secured term loan facility of up to $750.0 million from Royalty Pharma Development Funding, LLC, none of which had been drawn as of June 30, 2025. The company lists a Phase 3 RASolute 302 trial of daraxonrasib in second-line pancreatic cancer with an expected clinical readout in 2026, and notes that daraxonrasib received FDA Breakthrough Therapy Designation in June 2025.
The filing notes that no company product has been approved for commercial sale and that the company has never generated product revenue. Investors should weigh the rapid increase in operating expenses, the royalty and loan obligations that restrict operating flexibility and are secured by company assets, and the dependence on the outcome of pivotal trials.
02—Key points
Key Highlights
- Net loss of $247.8 million for Q2 2025 versus $133.2 million in Q2 2024; six-month net loss of $461.2 million versus $249.2 million.
- R&D expense of $224.1 million for the quarter, up from $134.9 million; G&A expense of $40.6 million, up from $21.7 million.
- Cash, cash equivalents and marketable securities of $2.1 billion at June 30, 2025, compared with $2.3 billion at December 31, 2024; accumulated deficit of $2.2 billion.
- June 2025 Royalty Purchase Agreement with Royalty Pharma provided $250.0 million upfront, recorded as a $245.1 million liability; up to an additional $1.0 billion in potential royalty purchases tied to milestones.
- Up to $750.0 million senior secured term loan facility with Royalty Pharma Development Funding, LLC; no amounts drawn as of June 30, 2025.
- Daraxonrasib received FDA Breakthrough Therapy Designation in June 2025 for previously treated metastatic pancreatic ductal adenocarcinoma with KRAS G12 mutations; the Phase 3 RASolute 302 readout is expected in 2026.
- Management believes existing cash will fund planned operations for at least 12 months; no products are approved for commercial sale.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 6, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| R&D Expenses | $224.13M$134.93M | +66.1% |
| Operating Expenses | $264.71M$156.64M | +69.0% |
| Operating Income | -$264.71M-$156.64M | −69.0% |
| Net Income | -$247.79M-$133.23M | −86.0% |
| EPS (Basic) | $-1.31$-0.81 | −61.7% |
| EPS (Diluted) | $-1.31$-0.81 | −61.7% |
| Shares Outstanding (Basic) | 188.58M165.14M | +14.2% |
| Shares Outstanding (Diluted) | 188.58M165.14M | +14.2% |
05—Questions
Frequently Asked Questions
How much cash did Revolution Medicines have, and how long will it last?
The company had $2.1 billion in cash, cash equivalents and marketable securities as of June 30, 2025. Management believes these resources will enable it to fund planned operations for at least 12 months following the date of the filing.
What did the Royalty Pharma deal involve?
In June 2025, the company received an upfront payment of $250.0 million in exchange for tiered royalty payments on worldwide net sales of daraxonrasib and, if approved for an overlapping indication, zoldonrasib. The filing also describes up to $1.0 billion of additional potential royalty purchases tied to trial readouts, regulatory approvals and sales milestones. The company accounts for the agreement as debt financing.
What is the term loan facility, and has it been used?
The facility, with Royalty Pharma Development Funding, LLC, provides up to $750.0 million in three $250.0 million tranches. The first tranche must be drawn within 45 days after FDA approval of daraxonrasib for metastatic PDAC if approval occurs by January 1, 2028. Term loans bear interest at three-month term SOFR (3.5% floor) plus 5.75% and are secured by substantially all company assets. No amounts had been drawn as of June 30, 2025.
Why did operating expenses increase so much?
Research and development expense rose $89.2 million for the quarter, driven mainly by a $46.7 million increase in daraxonrasib expenses, a $14.8 million increase in employee-related costs from higher headcount, and a $8.8 million increase in zoldonrasib expenses. G&A rose $18.9 million, including a $5.3 million increase in commercial preparation expenses.
What are the key near-term catalysts mentioned in the filing?
The company expects an enrollment completion for the RASolute 302 Phase 3 trial of daraxonrasib in 2025 with a clinical readout in 2026. It also plans to start a Phase 3 first-line PDAC monotherapy study and an adjuvant PDAC study in the second half of 2025, and a Phase 3 study in first-line RAS mutant NSCLC in 2026.
06—Continue